GPT-4o mini:The combination of venetoclax with FLAG-IDA (fludarabine, cytarabine, and idarubicin) has been studied in patients with relapsed acute myeloid leukemia (AML), particularly in those who are not candidates for intensive chemotherapy.
Clinical studies have reported promising results with this combination. The complete response (CR) rates can vary, but some studies have shown CR rates in the range of approximately 50% to 70% for patients treated with venetoclax in combination with FLAG-IDA.
It's important to note that individual patient factors, such as age, prior treatment history, and specific genetic mutations, can influence outcomes. For the most accurate and up-to-date information, it's advisable to refer to recent clinical trial data or published studies focusing on this specific treatment regimen.
GPT-4o mini:The combination of venetoclax with FLAG-IDA...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |